Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) – Stock analysts at Jefferies Financial Group upped their Q4 2019 earnings estimates for shares of Eiger Biopharmaceuticals in a research note issued to investors on Sunday, November 10th. Jefferies Financial Group analyst M. Raycroft now expects that the biotechnology company will post earnings per share of $1.48 for the quarter, up from their prior estimate of $1.45. Jefferies Financial Group also issued estimates for Eiger Biopharmaceuticals’ FY2022 earnings at $1.49 EPS and FY2023 earnings at $3.17 EPS.
Eiger Biopharmaceuticals (NASDAQ:EIGR) last announced its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.76) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.75) by ($0.01).
EIGR traded up $1.26 during midday trading on Tuesday, reaching $11.64. The company’s stock had a trading volume of 758,878 shares, compared to its average volume of 158,807. The firm has a market capitalization of $268.17 million, a price-to-earnings ratio of -3.05 and a beta of 1.02. The company has a current ratio of 6.83, a quick ratio of 6.83 and a debt-to-equity ratio of 0.44. Eiger Biopharmaceuticals has a 1 year low of $8.40 and a 1 year high of $15.33. The stock’s 50-day moving average is $10.58 and its 200-day moving average is $10.75.
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Bank of Montreal Can purchased a new position in Eiger Biopharmaceuticals during the second quarter valued at $28,000. Lindbrook Capital LLC purchased a new position in Eiger Biopharmaceuticals during the third quarter valued at $36,000. Tower Research Capital LLC TRC grew its stake in Eiger Biopharmaceuticals by 1,719.7% during the second quarter. Tower Research Capital LLC TRC now owns 4,895 shares of the biotechnology company’s stock valued at $52,000 after acquiring an additional 4,626 shares in the last quarter. Los Angeles Capital Management & Equity Research Inc. purchased a new position in Eiger Biopharmaceuticals during the second quarter valued at $113,000. Finally, Cubist Systematic Strategies LLC purchased a new position in Eiger Biopharmaceuticals during the second quarter valued at $179,000. Institutional investors and hedge funds own 82.92% of the company’s stock.
Eiger Biopharmaceuticals Company Profile
Eiger BioPharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare diseases in the United States and internationally. The company's lead program is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trial for treating hepatitis delta virus (HDV) infection.
Recommended Story: Day Trading
Receive News & Ratings for Eiger Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.